Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Cancer Research|February 11, 2012
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patientsSari Pesonen, Iulia Diaconu, Lotta Kangasniemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical OutcomesSanna Pikkusaari, Manuela Tumiati, Anni Virtanen, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2025
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer modelsSanteri A Pakola, Nea Ojala, Tatiana V Kudling, et al.
Cancer Gene Therapy|April 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomesTatiana V Kudling, Dmitrii Bychkov, James H A Clubb, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 29, 2010
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSFAnniina Koski, Lotta Kangasniemi, Sophie Escutenaire, et al.
Oncoimmunology|August 7, 2023
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancerTatiana V Kudling, James H A Clubb, Santeri Pakola, et al.
Oncoimmunology|April 10, 2026
<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolismMirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, et al.
Oncoimmunology|July 18, 2022
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regressionTatiana V Kudling, James H A Clubb, Dafne C A Quixabeira, et al.
Cancer Research|May 21, 2010
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patientsVincenzo Cerullo, Sari Pesonen, Iulia Diaconu, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Cancer Research|February 11, 2012
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patientsSari Pesonen, Iulia Diaconu, Lotta Kangasniemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical OutcomesSanna Pikkusaari, Manuela Tumiati, Anni Virtanen, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2025
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer modelsSanteri A Pakola, Nea Ojala, Tatiana V Kudling, et al.
Cancer Gene Therapy|April 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomesTatiana V Kudling, Dmitrii Bychkov, James H A Clubb, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 29, 2010
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSFAnniina Koski, Lotta Kangasniemi, Sophie Escutenaire, et al.
Oncoimmunology|August 7, 2023
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancerTatiana V Kudling, James H A Clubb, Santeri Pakola, et al.
Oncoimmunology|April 10, 2026
<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolismMirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, et al.
Oncoimmunology|July 18, 2022
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regressionTatiana V Kudling, James H A Clubb, Dafne C A Quixabeira, et al.
Cancer Research|May 21, 2010
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patientsVincenzo Cerullo, Sari Pesonen, Iulia Diaconu, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 7, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumorsElise Jirovec, Dafne C A Quixabeira, James H A Clubb, et al.
Pageof 13